Skip to main content area

Mirabegron: risk of severe hypertension and associated cerebrovascular and cardiac events

From MHRA Drug Safety Update:

Mirabegron is now contraindicated in patients with severe uncontrolled hypertension; advice about regular monitoring is being introduced because of cases of severe hypertension.

Advice for healthcare professionals from the MHRA:

  • Mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg, or both)
  • Blood pressure should be measured before starting treatment and monitored regularly during treatment, especially in patients with hypertension
  • Please report suspected side effects to mirabegron on a Yellow Card

Drug Safety Update vol 9 issue 3 October 2015: 1